NOVT (NOVT) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving NOVT (NOVT) right now is Medical Solutions demand: The Medical Solutions segment, which serves minimally invasive surgery, life sciences instrumentation, and patient monitoring, is roughly half of revenue and a key growth engine. Revenue (TTM) is ~$1.0 billion. If that keeps playing out, the setup is favourable; the risk to it is novanta trades at a high price-to-earnings multiple, so any shortfall in growth or margins can drive sharp share-price moves. No one can predict where NOVT trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive NOVT (NOVT) higher?
1. Medical Solutions demand.
The Medical Solutions segment, which serves minimally invasive surgery, life sciences instrumentation, and patient monitoring, is roughly half of revenue and a key growth engine. Novanta supplies embedded photonics, motion, and radio-frequency technologies to medical-device OEMs, giving it exposure to durable healthcare spending trends. Demand here tends to be less cyclical than industrial markets, which supports steadier revenue.
2. Automation and robotics.
The Automation Enabling Technologies segment sells precision motion, machine vision, and laser components into robotics, industrial automation, and laser materials processing. Novanta reported strong bookings growth with a book-to-bill ratio above 1.0 in early fiscal 2026, pointing to recovering order momentum. This unit ties Novanta to long-run automation and reshoring themes, though it is more sensitive to the industrial capital-spending cycle.
3. Acquisitions and margin expansion.
Novanta has a long track record of bolt-on acquisitions that add proprietary technology, broaden its OEM relationships, and expand its addressable market. Management pairs this with a focus on adjusted EBITDA margin expansion and pricing discipline. Successful integration is central to the growth story, since much of the company's reported revenue growth in a given year can come from deals rather than pure organic gains.
4. Improving order momentum.
In its Q1 fiscal 2026 report, Novanta cited bookings up about 37% year over year with double-digit bookings and revenue growth across all business units, and it raised its full-year revenue and earnings outlook. Rising bookings and a book-to-bill above 1.0 suggest the backlog is building. Whether that momentum converts into sustained organic growth depends on end-market demand holding up.
What could weigh on NOVT?
Novanta trades at a high price-to-earnings multiple, so any shortfall in growth or margins can drive sharp share-price moves. A large share of revenue comes from advanced industrial and semiconductor-adjacent markets that are cyclical and can slow quickly when customers cut capital spending. The company depends heavily on acquisitions for growth, which brings integration, goodwill, and balance-sheet risk if deals underperform. Because Novanta sells components embedded inside OEM products, it has customer-concentration and design-win risk, and results can be pressured by tariffs, supply-chain costs, and foreign-exchange swings given its global manufacturing and sales footprint.
Where NOVT trades today
A forecast starts from where the stock actually is. These are NOVT's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for NOVT as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a NOVT forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the NOVT guide and whether NOVT is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the NOVT outlook
The bottom line: what is driving NOVT (NOVT) is Medical Solutions demand, with revenue (ttm) at ~$1.0 billion. If that keeps playing out the setup is favourable; the risk is novanta trades at a high price-to-earnings multiple, so any shortfall in growth or margins can drive sharp share-price moves. No one can predict the price, so treat any NOVT forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around NOVT with Walnut
Use NOVT as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for NOVT (NOVT)?
+
No one can reliably predict where NOVT will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push NOVT higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive NOVT higher?
+
The main growth drivers are Medical Solutions demand; Automation and robotics; Acquisitions and margin expansion. Whether they play out is the real question, not a guaranteed path.
What are the risks to NOVT?
+
Novanta trades at a high price-to-earnings multiple, so any shortfall in growth or margins can drive sharp share-price moves. A large share of revenue comes from advanced industrial and semiconductor-adjacent markets that are cyclical and can slow quickly when customers cut capital spending. The company depends heavily on acquisitions for growth, which brings integration, goodwill, and balance-sheet risk if deals underperform. Because Novanta sells components embedded inside OEM products, it has customer-concentration and design-win risk, and results can be pressured by tariffs, supply-chain costs, and foreign-exchange swings given its global manufacturing and sales footprint.
Will NOVT stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. NOVT's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is NOVT a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the NOVT "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.